Albany, NY -- (SBWIRE) -- 02/15/2019 -- Anterior Stromal Puncture (ASP) is a procedure for the treatment of Recurrent Corneal Erosion (RCE), removal of keratoconus sub epithelial nodules, and improvement of contact lenses tolerance. The procedure involves surgical incisions (around 15 to 25 incisions spaced from 0.5 mm to 1 mm) using a short bent needle on the corneal surface. This is done to facilitate an inflammatory response serving as an anchor for the epithelium to be attached to the stroma. Anterior stromal puncture needles are available in standard sizes, usually 5/8 inch (25 gauge). These help ophthalmologists to perform desired number of incisions in the cornea. Ophthalmologists around the world have been adopting the anterior stromal puncture treatment method owing to the increase in healing rates in the treatment of RCE as demonstrated by various clinical trials.
Incidence of Recurrent Corneal Erosion (RCE) has been rising at a constant rate. Other methods for the treatment of Recurrent Corneal Erosion (RCE), including manual superficial keratectomy and laser phototherapeutic keratectomy (PTK), have been traditionally used owing to certain advantages such as low post-operative pain. Increasing incidence of patients suffering from Recurrent Corneal Erosion (RCE), drop in vision, pain, and photophobia, along with other dysfunctions of the eye, and various advantages of anterior stromal puncture (ASP) procedure such as ease of procedure, cost effectiveness, increased healing rates and safety of the procedure have been driving the increasing adoption of the stromal puncture needles in the global market.
Various clinical trials and studies have successfully demonstrated the efficiency of anterior stromal puncture needles in the treatment of indications concerning the cornea. These newer applications are expected to drive the global anterior stromal puncture needle market during the forecast period. However, rise in concerns about invasive techniques in the treatment of ophthalmic diseases among healthcare providers and ophthalmologists around the world is anticipated to tilt the balance of treatment methods toward laser stromal puncture technique. This is estimated to restrain the global anterior stromal puncture needle market during the forecast period.
Based on geography, the global anterior stromal puncture needle market can be segmented in to North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Higher prevalence of ophthalmic diseases in North America, increase in number of ophthalmic surgeries performed in the region, and growth in adoption of the safe and effective treatment procedure among patients and ophthalmologists are factors expected to boost the anterior stromal puncture needle market in North America during the forecast period.
However, gradual shift toward laser stromal puncture technique in the region is projected to hamper the anterior stromal puncture needle market in North America during the forecast period. Rapid increase in incidence of ophthalmic disorders in countries in Asia Pacific, especially those in Southeast Asia; and cost effectiveness of the anterior stromal puncture technique in treatment of RCE and other disorders are factors likely to augment the anterior stromal puncture needle market in Asia Pacific during the forecast period.
Request for TOC containing Tables and Figures:
Anterior stromal puncture needle is a highly fragmented market; numerous domestic and regional players operate in the less regulated and low entry barrier market. The market is characterized by a large number of small and large domestic players across different countries and regions, with few players operating on the global scale. Key players operating in the anterior stromal puncture needle market include Eagle Labs, Sigma Pharmaceuticals, LLC, AAAWholesaleCompany, and Eye Cure And Care.